Prospective, Multicentre, Randomized, Controlled, Cross-over Study on the Safety and Performance of the Biologic Fusion Option of DialogiQ Compared to Haemodialysis Without Biologic Fusion in Hypotension Prone Patients on Maintenance Haemodialysis

Not Applicable

Recruiting

• Conditions: Renal Dialysis
• Interventions: Device: BioLogic Fusion

• Registration Number: NCT06376968
• Lead Sponsor: B.Braun Avitum AG

Brief Summary

The goal of this prospective, randomized, controlled, cross-over, multicentric study is to demonstrate the safety of bioLogic Fusion in patients on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes. The main question it aims to answer is:

• Which is the number and percentage of individual sessions with reached prescribed post-dialysis body weight in the prescribed treatment time in each single session in hypotensive-prone patients on high-flux haemodialysis or hemodiafiltration within each patient with treatments performed with DialogiQ with (treatment A) or without (treatment B) the bioLogic Fusion option activated? Participants will in addition to their routine dialysis treatment undergo 2 physical examinations and regularly answer questionnaires.

A crossover design is used to compare treatments with or without the BioLogic Fusion function activated.

Detailed Description

Not available

Study Timeline

• Status Verified: 2024-04
• Study First Submitted: 2024-04-16
• Study First Submitted QC: 2024-04-18
• Study Start: 2024-04-22
• Study First Posted: 2024-04-22
• Last Update Submitted: 2024-04-26
• Last Update Posted: 2024-04-29
• Primary Completion: 2025-07
• Study Completion: 2025-08

Recruitment & Eligibility

• Status: RECRUITING
• Sex: All
• Target Recruitment: 56

Inclusion Criteria

• Male or female subjects ≥18 years of age
• Chronic bicarbonate standard high-flux haemodialysis or hemodiafiltration for at least 3 months
• Dialysis frequency 3 x per week
• Dialysis duration per session ≥ 4h
• Patient on chronic haemodialysis or hemodiafiltration prone to hypotensive episodes
• No residual renal function (definition: ≤100 ml urine/day)
• Stable dry body weight for at least 4 weeks
• Subjects who are willing to give a voluntary consent to participate in the study

Exclusion Criteria

• Simultaneous participation in another interventional clinical trial (drugs or medical devices studies)
• Vascular access insufficiency (mean blood flow <200ml/min)
• Patients treated with dialysis profiles: sodium profile, Ultrafiltration (UF) profile, and temperature profile
• Use of the BioLogic fusion function during the last 9 dialysis sessions recorded at the site (retrospective screening period)
• Pregnant or nursing women. Women of childbearing potential must agree to avoid pregnancy during the study period
• Factors which may interfere with full participation in the trial
• Any contra-indication to haemodialysis treatment per se, as described in the Instructions for Use (IFU)
• Any serious medical condition or disability, which in the opinion of the investigator limits the life expectancy and would preclude completion of the study

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: CROSSOVER

Arm && Interventions

Group	Intervention	Description
Standard dialysis followed by BioLogic Fusion	BioLogic Fusion	Patients will be dialysed first with standard dialysis with the BioLogic Fusion feature de-activated and then switched to the BioLogic Fusion feature activated
BioLogic Fusion followed by standard dialysis	BioLogic Fusion	Patients will be dialysed first with the BioLogic Fusion feature activated and then switched to standard dialysis with the BioLogic Fusion feature de-activated

Primary Outcome Measures

Name	Time	Method
Post-dialysis body weight	12 weeks	percentage of sessions with reached prescribed post-dialysis body weight

Trial Locations

Locations (1)

Policlinico S. Orsola - Malpighi - UOC Nefrologia, Dialisi e Ipertensione; 🇮🇹 Bologna, Emilia Romagna, Italy